Intellectual property (IP) ownership regarding proprietary drug pipelines, novel antibody engineering designs, and patented therapeutic molecules developed by biotechnology firms like Innate Pharma is legally retained by the corporate entity, its institutional collaborators, or joint-venture partners depending on specific co-development agreements. In pharmaceutical licensing partnerships—such as those established between Innate Pharma and major collaborators like AstraZeneca or Sobi—IP rights, commercialization milestones, and patent portfolios are co-managed or explicitly licensed under contractual terms that dictate regional manufacturing, distribution, and patent exclusivity rights for clinical assets.